Law.com Subscribers SAVE 30%

Call 855-808-4530 or email [email protected] to receive your discount on a new subscription.

Eminent Domain Law

ALM Staff & Law Journal Newsletters

A look at <i>Matter of Village of Port Chester v. Bologna</i>.

Development

ALM Staff & Law Journal Newsletters

In-depth analysis of an important ruling.

Features

Cooperatives & Condominiums

ALM Staff & Law Journal Newsletters

A key case is disussed.

When Is a Tenant Excused from Failure to Timely Exercise a Renewal Option?

Stewart E. Sterk

Suppose a lease gives a tenant an option to renew, but requires that the option be exercised by a specified date. What happens when the tenant exercises the option after the specified date?

Features

Litigation

ALM Staff & Law Journal Newsletters

Review of a pivotal case.

Formulaic Maintenance

Timothy M. Tippins

If Harry and Sally had not married but instead entered into a real partnership, say a law practice, and then dissolved it, what court would take seriously a claim by Harry that Sally should have to support him into the future simply because she earns more money than he did?

Features

Hedge Fund Valuation in Connection with Equitable Distribution

Steven Cusumano

Hedge fund valuation presents several challenges in the field of business valuation for the purposes of equitable distribution.

A Lasting Peace in Mass Torts

Mark Colins & Ryan Smethurst

Mass tort claims can create a tremendous financial and legal burden on a company. In-house counsel recommending settlement of a mass tort to company management, often at significant cost, must be confident that the settlement will buy a lasting and comprehensive peace. There are several key negotiating points that can help in-house counsel achieve such finality.

Features

Off-Label Communications

Areta L. Kupchyk & and Tracey B. Ehlers

While the FDA has had a long-standing policy of permitting drug, biologics, and medical device companies to respond to unsolicited requests for information about off-label use of their products, there has been significant discussion over what constitutes "unsolicited" in this context.

Practice Tip: Federal Jurisdiction and Venue

John L. Tate & Sarah Cronan Spurlock

With little fanfare or forewarning, the Federal Courts Jurisdiction and Venue Clarification Act of 2011 became effective Jan. 6, 2012. Signed into law on Dec. 7, 2011, the Act reforms or clarifies removal procedures, diversity jurisdiction, and federal venue.

Need Help?

  1. Prefer an IP authenticated environment? Request a transition or call 800-756-8993.
  2. Need other assistance? email Customer Service or call 1-877-256-2472.

MOST POPULAR STORIES

  • Surveys in Patent Infringement Litigation: The Next Frontier
    Most experienced intellectual property attorneys understand the significant role surveys play in trademark infringement and other Lanham Act cases, but relatively few are likely to have considered the use of such research in patent infringement matters. That could soon change in light of the recent admission of a survey into evidence in <i>Applera Corporation, et al. v. MJ Research, Inc., et al.</i>, No. 3:98cv1201 (D. Conn. Aug. 26, 2005). The survey evidence, which showed that 96% of the defendant's customers used its products to perform a patented process, was admitted as evidence in support of a claim of inducement to infringe. The court admitted the survey into evidence over various objections by the defendant, who had argued that the inducement claim could not be proven without the survey.
    Read More ›
  • In the Spotlight
    On May 9, 2003, the U.S. Attorney's Office for the District of Massachusetts announced that Bayer Corporation, the pharmaceutical manufacturer, had been sentenced and ordered to pay a criminal fine of $5,590,800 stemming from its earlier plea of guilty to violating the Federal Prescription Drug Marketing Act by failing to list with the FDA its drug product, Cipro, that was privately labeled for an HMO. Such listing is required under the federal Food, Drug &amp; Cosmetic Act. The Federal Prescription Drug Marketing Act, Pub. L. 100-293, enacted on April 22, 1988, as modified on August 26, 1992 by the Prescription Drug Amendments (PDA) Pub. L. 102-353, 106 Stat. 941, amended sections 301, 303, 503, and 801 of the Federal Food, Drug, and Cosmetic Act, codified at 21 U.S.C. '' 331, 333, 353, 381, to establish requirements for distributing prescription drug samples.
    Read More ›